contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


active-biotechs-nomination-committee-appointed-1

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Active Biotech operates in the pharmaceutical industry and focuses on the development of innovative treatments for cancer and autoimmune diseases. The company researches new therapies that can improve patient outcomes and quality of life. The project portfolio includes both small, orally active immunomodulatory molecules and antibody-based immunotherapy. The company operates globally. Active Biotech was founded in 1998 and is headquartered in Lund.

Active Biotech

In accordance with a decision made by the Annual General Meeting held on May 19, 2022, the Nomination Committee shall comprise the representatives for the three largest shareholders by votes...

<div class="mfn-preamble"><p><strong>In accordance with a decision made by the Annual General Meeting held on May 19, 2022, the Nomination Committee shall comprise the representatives for the three largest shareholders by votes, as per end of September 2022, and the Chairman of the Board.</strong></p></div><div class="mfn-body"><p>If a shareholder does not exercise its right to appoint a member, entitlement to appoint a member of the Nomination Committee transfers to the shareholder who is the next largest shareholder in terms of voting rights.</p><p>Based on the above, the Nomination Committee is composed with participants representing the largest shareholders in Active Biotech as of September 30, 2022, and consists of:</p><p>Michael Shalmi, chairman<br>Mats Arnhög, MGA Holding<br>Peter Lundkvist, 3:e AP Fonden<br>Peter Thelin, Sjuenda Holding</p><p>For the 2023 Annual General Meeting, the Nomination Committee shall prepare and submit proposals regarding the Chairman of the AGM, the number of Board members, a Chairman and Board members elected by the AGM, the fees and other renumerations to Board members and Board committee´s, number of auditors, the auditor, fees to auditors and election of a Nomination Committee.</p></div><div class="mfn-footer mfn-contacts mfn-39926fa7db58"><p><strong class="mfn-heading-1">For further information, please contact:</strong></p><hr><p>Helén Tuvesson,&nbsp;<em>CEO</em>, +46 46 19 21 56, <a rel="nofollow noopener" href="https://www.globenewswire.com/Tracker?data=iFG1kvVIp5pKUTaCk0JiGzw9dl5sOO_9c1qJkW85IwkJ2q3yfKNYaxNkYx6dheJqlz7uzyshFUzqp1r58eX0EwmkE0v707I8o0lPBbqYY8UvgU199yEyZAn5dlfWfZO4">helen.tuvesson@activebiotech.com</a><br>Hans Kolam,&nbsp;<em>CFO</em>, +46 46 19 20 44,&nbsp;<a rel="nofollow noopener" href="https://www.globenewswire.com/Tracker?data=MR5_ToeY_jOzyHsukO6TttPqhmPsAbWR4pvo7PzeBD-PVZpENlc1ykgW0p6jbew_WmkeAMSZFzoNVxkl8nuvvBVhljBcYy9uABVnK5yHhZKIfjtRDFjP5TNN-jwbPdiWCxnYxOQCr1gRU1L5udq8QNYq3vgqNIrmfSf1E8uCbUY4kMhRORUZ0ZdijKi9A-QPkK6sbjrvP0yHKc0XZwaRAWbewx1p63FAFCock9Mybrm3wdpGuMxvELcnTuccE0HQF7XVdn4dPrJgjbA4Z0m7IkCDp1nqkpJod1DlYbgCbuA=">hans.kolam@activebiotech.com</a></p></div><div class="mfn-footer mfn-about mfn-4dca1f9d12f2"><p><strong class="mfn-heading-1">About Active Biotech</strong></p><hr><p><strong>Active Biotech AB (publ) (NASDAQ Stockholm: ACTI)</strong> is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: The wholly owned small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is in a clinical phase I study with a topical ophthalmic formulation, to be followed by phase II-study for treatment of non-infectious uveitis. Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit&nbsp;<a rel="nofollow noopener" href="http://www.activebiotech.com">www.activebiotech.com</a>&nbsp;for more information.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="nofollow noopener" href="https://storage.mfn.se/7d522dab-65c4-465b-a6ff-8386d2d29419/active-biotechs-nomination-committee-appointed.pdf" class="mfn-generated mfn-primary">Active Biotech's nomination committee appointed</a></p></div>